WallStSmart

Insmed Inc (INSM)vsPlus Therapeutics Inc (PSTV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Insmed Inc generates 11533% more annual revenue ($606.42M vs $5.21M). PSTV leads profitability with a 0.0% profit margin vs -2.1%. INSM appears more attractively valued with a PEG of 1.09. INSM earns a higher WallStSmart Score of 39/100 (F).

INSM

Hold

39

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 6.7Quality: 6.3
Piotroski: 6/9Altman Z: -3.77

PSTV

Avoid

17

out of 100

Grade: F

Growth: 5.3Profit: 2.5Value: 6.7Quality: 5.0

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INSM0 strengths · Avg: 0/10

No standout strengths identified

PSTV0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

INSM4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
1.5%4/10

1.5% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Price/BookValuation
43.0x2/10

Trading at 43.0x book value

Return on EquityProfitability
-2.5%2/10

ROE of -2.5% — below average capital efficiency

PSTV4 concerns · Avg: 3.5/10
PEG RatioValuation
2.454/10

Expensive relative to growth rate

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$43.58M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : INSM

PEG of 1.09 suggests the stock is reasonably priced for its growth.

Bull Case : PSTV

PSTV has a balanced fundamental profile.

Bear Case : INSM

The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.

Bear Case : PSTV

The primary concerns for PSTV are PEG Ratio, EPS Growth, Market Cap.

Key Dynamics to Monitor

INSM profiles as a turnaround stock while PSTV is a value play — different risk/reward profiles.

INSM carries more volatility with a beta of 1.17 — expect wider price swings.

INSM is growing revenue faster at 1.5% — sustainability is the question.

PSTV generates stronger free cash flow (-6M), providing more financial flexibility.

Bottom Line

INSM scores higher overall (39/100 vs 17/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Insmed Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.

Plus Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacturing, and commercialization of treatments for patients with cancer and other diseases. The company is headquartered in Austin, Texas.

Want to dig deeper into these stocks?